Investors & Media

Corporate Profile

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has four programs in active clinical development.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News & Events

News Releases

February 26, 2024

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

February 20, 2024

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

January 17, 2024

NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com